ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2689 • 2014 ACR/ARHP Annual Meeting

    The CUL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus

    Peter H. Schafer1, Ying Ye2, Lei Wu3, Jolanta Kosek4, Zhihong Yang5, Liangang Liu5, Michael Thomas5, Maria Palmisano5 and Rajesh Chopra5, 1Celgene Corporation, Celgene Corporation, Summit, NJ, 286 Morris Avenue, Celgene Corporation, Summit, NJ, 3Department of Translational Development, Celgene Corporation, Summit, NJ, 4Translational Development, Celgene Corporation, Summit, NJ, 5Celgene Corporation, Summit, NJ

    Background/Purpose: CC-220 is an immunomodulatory compound that binds to cereblon (CRBN), part of the CUL4CRBN E3 ubiquitin ligase complex, which has been shown to ubiquitinate…
  • Abstract Number: 2667 • 2014 ACR/ARHP Annual Meeting

    First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy

    Khaled Alderaan1, Laurence S. Magder2 and Michelle Petri3, 1King Fahad Specilaist Hospital, Dammam, Saudi Arabia, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Preeclampsia complicates up to 35% of lupus pregnancies compared to 8% of general population pregnancies. SLE has up to a 3-fold increased rate of…
  • Abstract Number: 2635 • 2014 ACR/ARHP Annual Meeting

    Noncalcified Plaque Progression in Systemic Lupus Erythematosus

    Adnan Kiani1, Armin Zadeh2, Joao Lima2, Laurence S. Magder3 and Michelle Petri4, 11830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose:   Coronary atherosclerosis is a major cause of morbidity and mortality in SLE.  New technology, computed tomoangiography (CTA) can measure non-calcified coronary plaque (NCP),…
  • Abstract Number: 2648 • 2014 ACR/ARHP Annual Meeting

    Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus

    Xiangyang Huang1, Laurence S. Magder2 and Michelle Petri3, 1Sichuan University School of Medicine, Sichuan, China, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Depression affects as many as 30% of SLE patients.  Most studies of risk factors for depression among SLE patients have been cross-sectional, and thus…
  • Abstract Number: 2647 • 2014 ACR/ARHP Annual Meeting

    Predictors of Incident Seizure in Systemic Lupus Erythematosus

    Xiangyang Huang1, Laurence S. Magder2 and Michelle Petri3, 1Sichuan University School of Medicine, Sichuan, China, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: We identified the rate and risk factors for first occurrences of seizure based on a large closely followed longitudinal cohort of patients with systemic…
  • Abstract Number: 2622 • 2014 ACR/ARHP Annual Meeting

    Systemic LUPUS Erythematosus in Spanish Males

    Anne Riveros-Frutos1, Irma Casas2, Iñigo Rúa-Figueroa3, José Maria Pego-Reigosa4, M. Jesús García de Yebenes5, Alejandro Olivé6, Jose Rosas7, Paloma Vela8, Monica Ibanez Barcelo9, Vicente Torrente10, Ivan Castellvi11, Javier Narváez12, Mireia Moreno13, R. Blanco Alonso14, Víctor Martínez Taboada15, Jaime Calvo-Alen16, Mª Angeles Aguirre17, Mercedes Freire18, Enrique Raya19, Celia Erausquin20, Esther Uriarte21, Elvira Díez Álvarez22, Tomás Vázquez Rodríguez23, Antonio Fernández Nebro24, Eva Tomero25, Paloma García de la Peña26, Ana Sánchez Atrio27, Monica Fernández de Castro28, Antonio Zea29, Patricia Richi30, Francisco Lopez Longo31, María Galindo-Izquierdo32, Patricia Carreira33, Gema Bonilla34, Carlos Marras Fernández Cid35, Maria Loreto Horcada36, Carlos Montilla37, Blanca Hernández-Cruz38, José Marenco de la Fuente39, Marian Gantes40, Olaia Fernández Berrizbeitia41, Juan J. Alegre42, Ángela Pecondón Español43, Manuel Rodríguez-Gómez44, Victor Quevedo45, José Hernández Beiraín46 and Lucía Silva Fernández47, 1Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 2Preventive Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 3Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, 4Rheumatology, Hospital Meixoeiro, Vigo, Spain, 5Rheumatology, Research Unit of the SER, Madrid, Spain, 6Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 7Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, 8Rheumatology, Hospital General de Alicante. Spain, Alicante, Spain, 9H. Son Llatzer, Palma de Mallorca, Spain, 10Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, 11Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 12Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 13Rheumatology, Hospital Parc Taulí, Sabadell, Spain, 14Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 15Rheumatology, Marqués de Valdecilla, Santander, Spain, 16Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 17Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 18Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, 19Rheumatology, University Hospital San Cecilio, Granada, Spain, 20Rheumatology, Hospital Dr, Negrín, Las Palmas Gran Canarias, Spain, 21Rheumatology, Hospital de Donosti, San Sebastian, Spain, 22Rheumatology, Hospital de León. Spain, León, Spain, 23Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 24Rheumatology, Hospital Carlos Haya. Malaga, Malaga, Spain, 25Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 26Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, 27Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, 28Hospital Puerta del Hierro, Madrid, Spain, 29Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, 30Hospital Infanta Sofía, Madrid, Spain, 31Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, 32Rheumatology, Hospital 12 de octubre, Madrid, Spain, 33Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 34Rheumatology, Hospital La Paz, Madrid, Spain, 35Hospital Virgen de la Arrixaca, Murcia, Spain, 36Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, 37Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 38Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, 39Rheumatology, Hospital de Valme, Sevilla, Spain, 40Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, 41Rheumatology, Hospital de Basurto, Bilbao, Spain, 42Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, 43Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 44Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 45Rheumatology, Hospital de Monforte, Lugo, Spain, 46Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, 47Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain

    Background/Purpose: To describe the demographic, clinical and immunological manifestations in male patients with Systemic Lupus Erythematosus(SLE) Methods: Patients diagnosed of SLE that were in the…
  • Abstract Number: 1859 • 2014 ACR/ARHP Annual Meeting

    Age-Specific Predictors of Mortality in SLE

    Dominique Ibanez1, Dafna D. Gladman2 and Murray B. Urowitz2, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Mortality is 3 to 5 times greater in SLE patients then it is in the general population – especially among younger patients where it…
  • Abstract Number: 1652 • 2014 ACR/ARHP Annual Meeting

    Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus

    Adnan Kiani1, Laurence S. Magder2 and Michelle Petri3, 11830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Lupus nephritis eventually occurs in 50% of Caucasian SLE patients and 75% of African-Americans.  African Americans have a more severe presentation of SLE and…
  • Abstract Number: 1320 • 2014 ACR/ARHP Annual Meeting

    Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus

    Kyla D. Driest1, Mollie S. Sturm2, Sarah H. O'Brien3, Charles H. Spencer4 and Stacy P. Ardoin5, 1Rheumatology, OSU Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Hematology, Nationwide Children's Hospital, Columbus, OH, 4Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 5Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity…
  • Abstract Number: 1079 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Cardiac Arrhythmias in Systemic Lupus Erythematosus

    Gihyun Myung1, Lindsy J. Forbess2, Mariko L. Ishimori2, Sumeet Chugh1, Daniel Wallace1 and Michael H. Weisman1, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose Cardiovascular disease is a major cause of death among systemic lupus erythematosus (SLE) patients. Although the prevalence of atrial fibrillation (0.5-1%) and QT prolongation…
  • Abstract Number: 873 • 2014 ACR/ARHP Annual Meeting

    The Second Messenger, Cyclic GMP-AMP Dinucleotide (cGAMP) and the Enzyme, Cyclic GMP-AMP Synthase (cGAS), Are Expressed in Systemic Lupus Erythematosus

    Jie An1, Joshua Woodward2, Reynold Karr3, Thomas H. Teal4 and Keith B. Elkon1, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Microbiology, University of Washington, Seattle, WA, 3Department of Medicine, University of Washington, Seattle, WA, 4Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: The type I IFNs (IFN-I), are strongly associated with Systemic Lupus Erythematosus (SLE).  It is generally considered that IFN-I is induced by immune complexes…
  • Abstract Number: 700 • 2014 ACR/ARHP Annual Meeting

    Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease

    Ofir Elalouf1, Elizabeth Fireman2, David Levartovsky1, Ilana Kaufman1, Ori Rogovski3, Ori Elkayam1, Dan Caspi1 and Daphna Paran1, 1Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 2Pulmonary and Allergic diseases, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 3Internal Medicine ward, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Background/Purpose In a previous study, performed 9±3.6 years ago 74 asymptomatic patients with systemic lupus erythematosus (SLE) and or antiphospholipid syndrome (APS) who fulfilled the…
  • Abstract Number: 597 • 2013 ACR/ARHP Annual Meeting

    Low Complement (C3), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus

    Adnan Kiani1, Armin Zadeh2, Jens Vogel-Claussen1, Joao Lima2, Laurence S. Magder3 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD

    Background/Purpose: New technology (CTA) can measure non-calcified coronary plaque (NCP), which is highly unstable and prone to rupture.  We quantified NCP in SLE and determined…
  • Abstract Number: 574 • 2013 ACR/ARHP Annual Meeting

    Oral Candidiasis in Systemic Lupus Erythematosus

    Monthida Fangtham, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Candida is the most common opportunistic fungal infection identified in SLE. In a previous autopsy study, 14 percent of deaths in SLE patients were…
  • Abstract Number: 2899 • 2013 ACR/ARHP Annual Meeting

    Outcome Of Incidental Silent Strokes In Systemic Lupus Erythematosus

    Jamal Mikdashi, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Silent strokes are brain infarcts that lack clinically overt stroke-like symptoms and fail to come to clinical attention. The prevalence of incidentally detected acute/subacute…
  • « Previous Page
  • 1
  • …
  • 144
  • 145
  • 146
  • 147
  • 148
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology